Pharmacognosy · Anxiolytic · Piperaceae

Kava

Piper methysticum (Piperaceae) — a Pacific Island shrub whose root has anchored ceremonial and social life across Melanesia and Polynesia for centuries. Its kavapyrones show GABA-ergic activity underlying kava's traditional anxiolytic and muscle-relaxant use — but the same plant carries a well-documented hepatotoxicity risk that led France to prohibit its therapeutic use in 2003.

23 Primary Refs
6 Properties
Root Parts Used
✦ Researched
Last Updated August 13, 2026
Primary Source Wikiphyto · NCBI PubMed · Aust N Z J Psychiatry
Family Piperaceae
Piperaceae · Pacific Islands

Biological Overview

Piper methysticum is a perennial shrub, 1 to 4 meters tall, with enormous, very juicy, branched rhizomes weighing 2 to 10 kg, accompanied by numerous roots. It grows across Melanesia and Polynesia, on Pacific islands including Tonga, Samoa, Fiji, and Vanuatu.

HabitPerennial Shrub, 1–4m
Native RangeMelanesia & Polynesia
Kavalactone ContentMin. 3.5% (as kavain)
Regulatory StatusBanned in France (Therapeutic Use)
Botanical Classification

Taxonomy & Identification

Latin Name
Piper methysticum G. Forst.
Family
Piperaceae
Common Names
Kava, Kava-kava, Intoxicating Pepper, Awa
Parts Used
Rhizome and root
Rhizome Weight
2–10 kg, highly juicy and branched
Origin
Melanesia, Polynesia, Pacific islands
Ethnobotany & Traditional Use

History & Tradition

Kava is a product of the awa plant (Piper methysticum), traditionally used for ceremonial and medicinal purposes by Pacific Island peoples. It has long played a central role in religious ceremonies and holds an important social and ceremonial function across the cultures of Oceania, valued for its ability to make people more sociable.

Chewing the dried root produces a state of calm, languid intoxication that diminishes pain and induces prolonged local anesthesia of the tongue. At high doses, it produces motor disturbances, nausea, and tremors.

Kava's traditional preparation and consumption in the Pacific — typically as an aqueous extract — appears distinct from the hydro-alcoholic or acetone extracts more common in Western products, a difference that later became central to understanding kava's safety profile. 14

⚠ Banned for Therapeutic Use in France

Kava is prohibited for therapeutic marketing, dispensing, and use in France — except homeopathic dilutions of 5CH or higher — following a March 2003 government decision, driven by hepatotoxicity concerns. 1

Timeline

Pacific Ceremonial & Social Use

Traditional

Long used ceremonially and medicinally by Pacific Islanders, with a central role in social and ceremonial life across Oceania.

Western Anxiolytic Interest

20th Century

Adopted in Western herbal medicine as an anxiolytic, with kavapyrones identified as the active constituents.

Hepatotoxicity Concerns Emerge

Early 2000s

Case reports of fulminant hepatitis linked to kava extracts prompted regulatory reviews across Europe. 8

French Prohibition & Ongoing Review

2003–Present

France banned therapeutic kava (except high homeopathic dilutions) in March 2003; researchers have since proposed that poor-quality extracts, aflatoxin contamination, or extraction solvent may explain the toxicity gap between Pacific traditional use and Western cases. 91112

The Key Compounds

Kavapyrones (Kavalactones) — Deep Dive

The family of six lactones behind kava's anxiolytic reputation, and the compounds used to standardize commercial products.

🧬

Six Major Kavapyrones

Kavain, dihydrokavain (marindinin), methysticin, dihydromethysticin, yangonin, and desmethoxyyangonin make up a minimum of 3.5% kavalactones, expressed as kavain.

🎯

GABA-ergic Activity

Kavapyrones exert GABA-ergic activity, a core mechanism behind kava's calming and anxiolytic effects. 4

🧪

MAO-B Inhibition

Kava shows monoamine oxidase B (MAO-B) inhibiting activity. 3

⚡

Sodium Channel & GABA Receptor Modulation

Opens sodium channels and modulates the GABA receptor, contributing to effects resembling both neuroleptics and benzodiazepines.

⚠ Quality & Extraction Matter

Toxicity may trace to processing, not just the plant itself.

Toxicity appears linked to excessive doses, prolonged use, co-administration of other hepatotoxic substances, or poor-quality extracts — not necessarily kava itself. Aflatoxins or mycotoxins from Aspergillus and other fungi (from poor storage conditions) are suspected contributors to reported hepatotoxicity, and these problems are not seen in countries with traditional kava consumption. 9121314

Pharmaceutical Preparations

Parts Used & Available Forms

The rhizome and root are used medicinally, prepared across two documented forms — both prohibited in France below the 5CH homeopathic dilution threshold.

Dry Extract

Standardized to 20–70% total kavapyrones. 1

Dry Extract

Mother Tincture

Tincture of the underground part (rhizome and root).

Mother Tincture

Clinical Dosimetry

Dosages

Note the large gap between therapeutic dosing and traditional Pacific serving strength — duration and monitoring should be set by a qualified practitioner, where legally available.

Form Dose Frequency Context Notes
Standardized Extract 60–120 mg total kavapyrones Daily Anxiety, stress, instability Traditional/clinical dosing range cited in the source.
Traditional Kava Drink 600–800 mg total kavalactones Per cup Ceremonial/social (Pacific tradition) Far exceeds therapeutic dosing; reflects traditional preparation strength in kava bars. 2
Phytochemistry

Composition

Root composition only — no gemmotherapy (bud) or essential-oil fraction is documented for this species.

Root — Primary Constituents

KawapyronesKavain, dihydrokavain, methysticin, dihydromethysticin, yangonin, desmethoxyyangonin — compounds responsible for kava's activity
Min. 3.5%
Essential OilPresent in small quantity
Trace
FlavonoidsChalcones and flavones, including flavokawain B
Present
StarchAbundant
Abundant

Plant Properties — Pharmacodynamics

Six pharmacodynamic properties are documented for kava, anchored in its kavapyrone–GABA pathway.

6 Properties Sedative GABA-ergic Preclinical + Traditional
😴

Sedative & Hypnotic

Mild narcotic effect, antagonizes strychnine-induced convulsions, hypnotic and narcosis-potentiating, induces sleep via action on limbic structures, sedative and tranquilizing.

🧠

GABA-ergic

Kavapyrones show GABA-ergic activity. 4

🧪

MAO-B Inhibiting

Inhibits monoamine oxidase B. 3

💊

Analgesic (Non-Opioid)

Analgesic effect not antagonized by naloxone, indicating a non-opioid mechanism.

🌀

Musculotropic Spasmolytic

Myorelaxant effect of the mephenesin type.

🧫

Pro-Apoptotic (Chalcones)

Certain chalcones (flavokawain B) induce apoptosis in adenoid cystic carcinoma and prostate cancer cell lines. 56

Clinical Applications

Clinical Indications

Kava's traditional and studied use centers on anxiety relief and skeletal muscle relaxation, alongside preliminary oncology research.

😌
Anxiety & Stress Relief
Primary Indication
  • Relaxation & Euphoria: consumption produces an astringent sensation in the mouth, followed by relaxation and euphoria during which fatigue and anxiety disappear.
  • Restful Sleep: a high dose produces restful drowsiness followed by an anxiety-free, refreshed waking.
💪
Skeletal Muscle Relaxation
Traditional / Preclinical
  • Low-Dose Effect: low doses relax skeletal muscles with mild euphoria, likely through activation of dopaminergic and serotonergic neurons.
🔬
Investigational Oncology
Preliminary Interest
  • Pro-Apoptotic Chalcones (Preclinical): flavokawain B induces apoptosis in adenoid cystic carcinoma and hormone-refractory prostate cancer cell lines. 56
⚠️
Use Considerations
Clinical Precautions
  • Traditional Practices: a specific traditional aphrodisiac use has been described in the ethnobotanical literature. 7
  • Not Recommended For: pregnancy, breastfeeding, endogenous depression, or use before operating machinery.
Pharmacodynamics

Mode of Action

Kava's psychoactive effects converge on ion-channel and receptor-level activity distinct from most botanical anxiolytics.

💊

Neuroleptic & Benzodiazepine-Like Effects

Effects reminiscent of neuroleptics and benzodiazepines have led kava to be described as a natural psychotropic.

⚡

Sodium Channel Opening

Opens Na+ channels, contributing to kava's neuroactive profile.

🧠

GABA Receptor Modulation

Modulates the GABA receptor, complementing kavapyrones' independently documented GABA-ergic activity. 4

🚫

Non-Opioid Analgesia

Analgesic effect is not antagonized by naloxone, indicating the mechanism does not run through opioid receptors.

Risk Profile

Safety & Regulatory Status

Kava carries a documented hepatotoxicity risk and a specific legal prohibition in France — genuinely different from most botanicals covered on this site.

⚠ Genuine, Serious Risks Specific to This Plant

Read Before Considering Kava

  • Hepatotoxicity: regarded as hepatotoxic by French regulatory authorities (AFSSAPS); suspected of elevating gamma-GT and linked to case reports of fulminant hepatitis. 8
  • Banned for therapeutic use in France: prohibited for marketing, dispensing, and therapeutic use since March 2003, except homeopathic dilutions of 5CH or higher. 1
  • Contraindicated in pregnancy, breastfeeding, and endogenous depression.
  • Not for use with machinery: prohibited in combination with driving or operating machinery.
  • CYP2E1 inhibition: affects metabolism of alcohol, sedatives, and tranquilizers; dyskinesias are specifically potentiated by alcohol.
⚠️

Adverse Effects

  • Dyskinesias: potentiated by alcohol.
  • Hepatotoxicity: suspected gamma-GT elevation and case reports of fulminant hepatitis. 8
  • Toxicity Contributing Factors: excessive doses, prolonged use, co-administration of other hepatotoxic substances, poor-quality extracts, or fungal contamination — issues not seen in countries with traditional aqueous-extract consumption. 9121314
🚫

Contraindications & Interactions

  • Pregnancy, Breastfeeding & Endogenous Depression: contraindicated.
  • Machinery Operation: contraindicated.
  • CYP2E1 Inhibition: affects metabolism of alcohol, sedatives, and tranquilizers.
  • Regulatory Status: banned for therapeutic use in France except homeopathic dilutions ≥5CH, per the March 2003 decision. 1
Clinical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice. Kava is prohibited for therapeutic use in France and restricted or banned in a number of other countries; check current local regulations before considering use, and consult a qualified healthcare provider given its documented hepatotoxicity risk.
Common Questions

Frequently Asked Questions

What is kava used for?
Kava is traditionally used ceremonially and socially across the Pacific Islands, and has been used in Western herbal medicine for anxiety, stress, and mild skeletal muscle relaxation.
How does kava work?
Kavapyrones show GABA-ergic activity and inhibit monoamine oxidase B (MAO-B). Kava also opens sodium channels and modulates the GABA receptor, producing effects described as reminiscent of neuroleptics and benzodiazepines.
What is the typical kava dosage?
Traditional and clinical use cites 60–120 mg of total kavapyrones daily for anxiety, stress, or instability. In kava bars, a single traditionally prepared cup may contain 600–800 mg of total kavalactones — far higher than typical therapeutic dosing.
Is kava legal?
In France, kava has been prohibited for therapeutic marketing, dispensing, and use since a March 2003 government decision, except for homeopathic dilutions of 5CH or higher. Legal status varies by country.
Is kava safe? What's the hepatotoxicity concern about?
Kava is regarded as hepatotoxic by French regulatory authorities, with case reports of fulminant hepatitis. Researchers have proposed that excessive doses, prolonged use, poor-quality extracts, or fungal contamination may explain the toxicity seen in some Western cases, which is not observed in Pacific countries with traditional aqueous-extract consumption.
Why does kava numb the tongue?
Chewing the dried root produces a prolonged local anesthetic effect on the tongue, part of the traditional intoxicating and pain-relieving effect described in Pacific Island use.
Can I drink alcohol while using kava?
This is not recommended. Kava-related dyskinesias are potentiated by alcohol, and kava inhibits CYP2E1, an enzyme involved in alcohol metabolism.
Is kava safe during pregnancy?
No. Kava is contraindicated during pregnancy, breastfeeding, and in endogenous depression.
Sources

Bibliography

↑1. Décision du 13 mars 2003 portant interdiction de la mise sur le marché, à titre gratuit ou onéreux, de la délivrance et de l'utilisation à des fins thérapeutiques du kava et de produits en contenant. Journal Officiel de la République Française, n°72, March 26, 2003, p.5367, texte n°52.
Legifrance (Official Text) →
↑2. Dossier spécial Nouvelle-Calédonie et Polynésie française : Le kava, Piper methysticum G. Forst, à Tanna (Vanuatu). Ethnopharmacologia, n°46, December 2010.
↑3. Mazzio E, Deiab S, Park K, Soliman KFA. High throughput screening to identify natural human monoamine oxidase B inhibitors. Phytother Res. 2013;27(6):818–828.
Full Text (PMC) →
↑4. Shi Y, Dong JW, Zhao JH, Tang LN, Zhang JJ. Herbal insomnia medications that target GABAergic systems: a review of the psychopharmacological evidence. Curr Neuropharmacol. 2014;12(3):289–302.
PubMed: PMID 24851093 →
↑5. Zhao X, Chao YL, Wan QB, et al. Flavokawain B induces apoptosis of human oral adenoid cystic cancer ACC-2 cells via up-regulation of Bim and down-regulation of Bcl-2 expression. Can J Physiol Pharmacol. 2011.
PubMed: PMID 22115332 →
↑6. Tang Y, Li X, Liu Z, Simoneau AR, Xie J, Zi X. Flavokawain B, a kava chalcone, induces apoptosis via up-regulation of death-receptor 5 and Bim expression in androgen receptor negative, hormonal refractory prostate cancer cell lines and reduces tumor growth. Int J Cancer. 2010;127(8):1758–1768.
PubMed: PMID 20112340 →
↑7. Hostettmann K. Tout savoir sur les aphrodisiaques naturels. Favre SA, Lausanne, 2000.
↑8. AFSSAPS (Agence française de sécurité sanitaire des produits de santé). Assessment report on kava hepatotoxicity.
AFSSAPS Report (PDF) →
↑9. Teschke R. Kava hepatotoxicity — a clinical review. Ann Hepatol. 2010;9(3):251–265.
PubMed: PMID 20720265 →
10. Teschke R. Kava hepatotoxicity: pathogenetic aspects and prospective considerations. Liver Int. 2010;30(9):1270–1279.
PubMed: PMID 20630022 →
↑11. Showman AF, Baker JD, Linares C, et al. Contemporary Pacific and Western perspectives on `awa (Piper methysticum) toxicology. Fitoterapia. 2015;100:56–67.
PubMed: PMID 25464054 →
↑12. Teschke R, Gaus W, Loew D. Kava extracts: safety and risks including rare hepatotoxicity. Phytomedicine. 2003;10(5):440–446.
PubMed: PMID 12834011 →
↑13. Teschke R, Qiu SX, Xuan TD, Lebot V. Kava and kava hepatotoxicity: requirements for novel experimental, ethnobotanical and clinical studies based on a review of the evidence. Phytother Res. 2011;25(9):1263–1274.
PubMed: PMID 21442674 →
↑14. Ernst E. A re-evaluation of kava (Piper methysticum). Br J Clin Pharmacol. 2007;64(4):415.
Full Text (PMC) →

Additional Sources

Sarris J, LaPorte E, Schweitzer I. Kava: a comprehensive review of efficacy, safety, and psychopharmacology. Aust N Z J Psychiatry. 2011;45(1):27–35.
PubMed: PMID 21073405 →
Sarris J. Herbal medicines in the treatment of psychiatric disorders: a systematic review. Phytother Res. 2007;21(8):703–716.
PubMed: PMID 17562566 →
Wichtl M, Anton R. Plantes thérapeutiques: Tradition, pratique officinale, science et thérapeutique. Tec & Doc, Cachan, 1999, p.300.
Bruneton J. Pharmacognosie, Phytochimie, Plantes médicinales. Tec & Doc, 1997, p.263.
Young RL, Hylin JW, Plucknett DL, Kawano Y, Nakayama RT. Analysis for kawa pyrones in extracts of Piper methysticum. Phytochemistry. 1966;5(4):795–798.
Frantz S. Activité anxiolytique de molécules d'origine naturelle: Contribution à l'étude du Kawa, du Millepertuis et de l'Eschscholtzia. Pharmacy thesis, Université Henri Poincaré, Nancy 1, October 2001.
Escher M, Desmeules J, Giostra E, Mentha G. Hepatitis associated with kava, a herbal remedy for anxiety. BMJ. 2001;322(7279):139.
Full Text (PMC) →
Stevinson C, Huntley A, Ernst E. A systematic review of the safety of kava extract in the treatment of anxiety. Drug Saf. 2002;25(4):251–261.
PubMed: PMID 11994028 →
Teschke R, Schwarzenboeck A, Hennermann KH. Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases. Eur J Gastroenterol Hepatol. 2008;20(12):1182–1193.
PubMed: PMID 18989142 →
Bilia AR, Gallon S, Vincieri FF. Kava-kava and anxiety: growing knowledge about the efficacy and safety. Life Sci. 2002;70(22):2581–2597.
PubMed: PMID 12269386 →